Tongue Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029843 (Tongue Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment